GBIO
Generation Bio Co.5.38
-0.01-0.19%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
36.25MP/E (TTM)
-Basic EPS (TTM)
-9.37Dividend Yield
0%Recent Filings
8-K
8-K
CEO transition announced
Generation Bio announced CEO Geoff McDonough's resignation effective October 31, 2025, amid its strategic alternatives review, with him transitioning to Board Chair under a separation deal including $700,000 cash severance, $300,000 bonus payment, and 25% equity vesting acceleration. Yalonda Howze, former Chief Legal Officer, steps in as Interim CEO and President with $575,000 base salary. Transition smooths leadership amid uncertainties.
10-Q
Q2 FY2025 results
Generation Bio's Q2 collaboration revenue dipped to $0.8M from $4.1M y/y, yet YTD revenue climbed 16% to $9.5M on a $5.3M research plan adjustment. Operating loss narrowed to $22.9M from $23.3M y/y, with R&D steady at $15.5M and G&A down 19% to $7.7M amid headcount cuts; net loss edged up to $20.9M, or $(3.12) per share on 6.7M diluted shares. Cash burn slowed, with $45.2M used in operations versus $53.2M y/y, leaving $141.4M in cash and securities at quarter-end—no debt, but a $31M Seyon Lease settlement looms in Q3. The 90% workforce reduction starts mid-August to stretch runway during strategic alternatives hunt. Litigation shadows cash flows.
8-K
ctLNP data sparks strategic review
Generation Bio unveiled promising data on its ctLNP delivery system, achieving first-ever siRNA delivery to T cells in non-human primates with potent knockdown of targets like LAT1 and VAV1, potentially targeting autoimmune diseases. Yet, facing lengthy development timelines, the company is exploring strategic alternatives with TD Cowen advising on options like mergers or asset sales, while implementing a phased 90% workforce cut by October. Cash stood at $141.4 million as of June 30, 2025, dropping to about $100 million post-$31 million lease settlement. This pivot underscores delivery tech's promise amid funding pressures.
8-K
1-for-10 reverse split announced
Generation Bio Co. filed for a 1-for-10 reverse stock split, effective July 21, 2025, at 5:00 p.m. ET, slashing outstanding shares from 67.3 million to 6.7 million. This move aims to boost the per-share price and meet Nasdaq's minimum bid requirement for continued listing. Trading resumes split-adjusted on July 22 under 'GBIO' with new CUSIP 37148K 209. No fractional shares; cash payments instead. Yet compliance isn't guaranteed amid biotech risks.
CBIO
Crescent Biopharma, Inc.
12.92-0.29
GERN
Geron Corporation
1.34+0.01
GLTO
Galecto, Inc.
30.00-1.60
GRI
GRI Bio, Inc.
0.48+0.00
GTBP
GT Biopharma, Inc.
0.72+0.09
IMA
ImageneBio, Inc.
6.25+0.08
INAB
IN8bio, Inc.
1.50-0.10
PASG
Passage Bio, Inc.
9.45-0.60
RGBP
Regen Biopharma, Inc.
0.01-0.00
TRML
Tourmaline Bio, Inc.
47.98+47.98